Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026 Lead Investing
Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia Lead Investing
OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026 Lead Investing
Pan American Silver Announces Results of Annual General and Special Meeting Precious Metals Investing
Silver X Delivers Strong 2025 Financial Results with Margin Expansion and Clear Path to Growth Lead Investing
